Background

PD-L1 (Programmed cell death 1 ligand 1), also known as CD274, is a ligand of programmed death-1 (PD-1). PD-1 also known as CD279, is an important negative costimulatory molecule. PD-1 and PD-L1 signaling pathway plays an important role in infection immunity, tumor immunity, and transplantation immunity, which makes targeting PD-1/PD-L1 signaling pathway a research hotspot for treating tumors. PD-1/PD-L1 antibody can reverses the tumor immune microenvironment by blocking the PD-1/PD-L1 signaling pathway and enhances the endogenous anti-tumor immune effect.

Marketed Drug

The Show of Product

The PD-L1 protein (Recombinant Human Programmed cell death 1 ligand 1(CD274), partial (Active)) provided by CUSABIO has a high purity (>95%) and its activity has also been verified experimentally. The details are shown below:

	Western Blotting (WB) (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
	Activity Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL.

Related Products

PD-L1 related products involve ELISA, antibody and protein products of PD-L1, as well as PD-1 products.

Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit (CSB-E13644h)

PD-L1 Monoclonal Antibody (ELISA, WB, IHC, IF, FC) (CSB-MA878942A1m)

PDCD1 Antibody (ELISA, WB, IHC, IF) (CSB-PA619964LA01HU)

CD274 Antibody (ELISA, WB, IP, IHC, IF, FC) (CSB-PA004911GA01HU)